Current treatments for patients with pancreatic cancer offer limited benefits. In this study, we applied alkalization therapy, which was efficacious for other solid tumors at our clinic, to stage 4 pancreatic cancer patients, and investigated its effect on disease prognosis. Patients with metastatic pancreatic cancer who were treated at Karasuma Wada Clinic in Kyoto, Japan, between January 2011 and April 2022, were included in the study. All patients received alkalization therapy (a combination of an alkaline diet, bicarbonate, and citric acid administration), alongside standard chemotherapy. Urine samples were collected to assess urine pH as a marker of whole-body alkalization. In the 98 patients analyzed, the median overall survival (OS) from the time of diagnosis was 13.2 months. Patients with a mean urine pH of 7.5 or greater had a median OS of 29.9 months, compared with 15.2 months for those with a mean urine pH of 6.5 to 7.5, and 8.0 months for those with a mean urine pH of less than 6.5, which suggests a trend of a longer OS in patients with a higher urine pH (p= 0.0639). Alkalization therapy may offer a viable approach to extending the survival of stage 4 pancreatic cancer patients, who typically have an unfavorable prognosis.
目前针对胰腺癌患者的治疗方案获益有限。本研究将我院临床中对其他实体瘤有效的碱化疗法应用于IV期胰腺癌患者，并探讨其对疾病预后的影响。研究对象为2011年1月至2022年4月期间在日本京都乌丸和田诊所接受治疗的转移性胰腺癌患者。所有患者在标准化疗基础上均接受碱化疗法（包括碱性饮食、碳酸氢盐及柠檬酸联合干预），通过检测尿液pH值作为全身碱化程度的生物标志物。在纳入分析的98例患者中，自确诊起中位总生存期为13.2个月。平均尿pH值≥7.5的患者中位总生存期达29.9个月，而平均尿pH值6.5-7.5组为15.2个月，平均尿pH值<6.5组仅为8.0个月，数据显示尿pH值较高患者呈现更长生存期的趋势（p=0.0639）。对于预后通常较差的IV期胰腺癌患者，碱化疗法可能为延长其生存期提供可行路径。
肿瘤(癌症)患者之家